SCHEMBL6105484

SCHEMBL6105484

C[C@H](N)Cc1cccc(CN(C(=O)O)C(C)(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TAAR1 Q96RJ0 4/20 0.46
SLC6A2 P23975 2/20 0.46
MAOA P21397 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
CYP2A6 P11509 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
LMNA P02545 3/20 0.46
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
PNMT P11086 1/20 0.44
ALDH1A1 P00352 1/20 0.43
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6105491 1.00 MEN1 (0.48) MEN1KMT2AHTTL3MBTL1TAAR1
SCHEMBL689321 0.84 MEN1 (0.51) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL186800 0.82 MEN1 (0.53) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL395409 0.81 MEN1 (0.51) MEN1KMT2AHTTL3MBTL1MAOA
SCHEMBL8773482 0.79 MEN1 (0.69) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL5343307 0.79 MEN1 (0.53) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL67173 0.78 RIPK1 (0.56) MEN1KMT2AHTTL3MBTL1TAAR1
SCHEMBL2694899 0.78 MEN1 (0.51) MEN1KMT2AHTTL3MBTL1SIGMAR1
SCHEMBL17257957 0.75 MEN1 (0.49) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL2173709 0.75 MEN1 (0.52) MEN1KMT2AHTTL3MBTL1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060161001-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060161001-A1 Substituted heterocyclic compounds and methods of use MAPT, MYLK2, IAPP MEN1 190/4885KMT2A 1976/4885HTT 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.